Natera, Inc. ($NTRA) Stock Forecast: Down 7.7% Today

What is Natera, Inc.?

Natera, Inc. (NASDAQ: NTRA) specializes in genetic testing services, especially in women's health and oncology, and has recently announced robust financial results for Q1 2026.

Why is Natera, Inc. going down?

NTRA stock is down 7.7% on May 8, 2026 17:06

• Despite strong revenue growth driven by successful products like Fetal Focus and Signatera MRD test, Natera faced a bearish movement in its stock, potentially linked to a wider net loss reported in the same quarter, raising concerns about profitability.
• The missed EPS estimate and increased operating expenses leading to a higher net loss are likely factors contributing to the negative market sentiment towards Natera.
• Investors may be concentrating on the company's ability to manage expenses and bottom line performance, somewhat overshadowing the positive revenue growth and raised revenue guidance for the full year.
• The market's response could also be influenced by the stock's recent underperformance compared to the broader market, despite surpassing revenue expectations, suggesting a possible mismatch in investor expectations and market valuation.

NTRA Price Chart

NTRA Technical Analysis

NTRA News

Natera, Inc. (NASDAQ:NTRA) Q1 2026 Earnings Call Transcript

Natera, Inc. reported strong first-quarter 2026 results with $697 million in revenue, a 39% year-over-year increase, driven by rapid growth in women's health and record oncology volumes. The company's Fetal Focus product launch is exceeding expectations, and its Signatera MRD test is gaining significant traction, including data supporting surgery avoidance in certain cancer patients. Natera has also raised its full-year revenue guidance by over $120 million and increased its gross margin guidance to 65%, while expecting a significant market expansion with its upcoming Japan launch and early cancer detection initiatives.

https://www.insidermonkey.com/blog/natera-inc-nasdaqntra-q1-2026-earnings-call-transcript-1757122/

Natera Reports First Quarter 2026 Financial Results

Natera, Inc. announced strong financial results for the first quarter of 2026, with total revenues increasing by 38.8% to $696.6 million and processing over one million tests for the first time. The company reported a gross margin of 64.7% and achieved positive cash inflow of $11.8 million. Natera also raised its 2026 annual revenue guidance to $2.74 billion - $2.82 billion, driven by increased adoption of its Signatera and Fetal Focus products.

https://www.biospace.com/press-releases/natera-reports-first-quarter-2026-financial-results

Natera (NTRA) grows Q1 2026 revenue to $696.6M while net loss widens

Natera, Inc. (NTRA) reported a significant increase in total revenues to $696.6 million in Q1 2026, up from $501.8 million in the prior-year quarter, primarily driven by product revenues. Despite this robust top-line growth, the company's net loss widened to $85.1 million from $66.9 million, as research and development and selling, general, and administrative expenses also expanded substantially. The company maintains a strong liquidity position with $1.09 billion in cash and equivalents, underscoring its continued investment in product development and commercialization efforts.

https://www.stocktitan.net/sec-filings/NTRA/10-q-natera-inc-quarterly-earnings-report-e21ee2b27802.html

Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Natera (NTRA) reported Q1 2026 revenue of $696.64 million, a 38.8% increase year-over-year, exceeding the Zacks Consensus Estimate by 13.26%. Despite this, the EPS came in at -$0.56, missing the consensus estimate of -$0.53. Key metrics like tests processed and product revenues surpassed analyst expectations, though the stock's recent performance lagged the broader market.

https://sg.finance.yahoo.com/news/natera-ntra-q1-earnings-taking-230005769.html

Natera (NTRA) lifts 2026 outlook after 39% Q1 revenue surge

Natera reported a strong first quarter in 2026 with revenue surging 38.8% to $696.6 million, driven by increased test volumes across oncology and women's health. While the company still posted an increased net loss of $85.1 million due to higher operating expenses, it raised its full-year 2026 revenue guidance to $2.74–$2.82 billion and expects positive net cash inflow. This positive outlook is supported by record test volumes and significant momentum in its Signatera minimal residual disease test.

https://www.stocktitan.net/sec-filings/NTRA/8-k-natera-inc-reports-material-event-df549edda1b1.html

Trending Today

XRP ($XRP) Crypto Forecast: Up 5.3% Today

Aave ($AAVE) Crypto Forecast: Up 5.3% Today

Natera, Inc. Price History

08.04.2026 - NTRA Stock was down 7.7%

• Despite strong revenue growth driven by successful products like Fetal Focus and Signatera MRD test, Natera faced a bearish movement in its stock, potentially linked to a wider net loss reported in the same quarter, raising concerns about profitability.
• The missed EPS estimate and increased operating expenses leading to a higher net loss are likely factors contributing to the negative market sentiment towards Natera.
• Investors may be concentrating on the company's ability to manage expenses and bottom line performance, somewhat overshadowing the positive revenue growth and raised revenue guidance for the full year.
• The market's response could also be influenced by the stock's recent underperformance compared to the broader market, despite surpassing revenue expectations, suggesting a possible mismatch in investor expectations and market valuation.

14.03.2026 - NTRA Stock was up 5.1%

• William Blair started covering Natera with an Outperform rating, emphasizing the company's market position and growth prospects, likely boosting investor confidence.
• A favorable interim futility analysis from Allogene Therapeutics' trial utilizing Natera's CLARITY™ MRD assay showed promising results in large B-cell lymphoma, contributing to the positive sentiment surrounding Natera.
• A court ruling ordering a 30% ongoing royalty for Natera in a patent dispute is a significant win, reinforcing the company's intellectual property rights and potentially increasing future revenue.
• Despite a decrease in price, the increase in trading volume after the legal victory indicates investor interest and optimism in Natera's future financial performance, as they anticipate the impact of these events on upcoming earnings.

14.03.2026 - NTRA Stock was up 5.8%

• Today's positive performance by Natera is linked to William Blair's initiation of coverage on the company, endorsing its strong position in diagnostic markets and growth potential.
• The encouraging interim futility analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial, which uses Natera's CLARITY™ MRD assay, also contributed to the optimistic outlook by demonstrating successful MRD clearance in high-risk patients.
• Furthermore, a recent court ruling that mandates a 30% ongoing royalty payment to Natera in a patent dispute is seen as a significant victory for the company, reinforcing its intellectual property rights and hinting at future financial gains.
• Despite concerns such as potential overvaluation and insider sales, Natera's leadership in the market, early-mover advantage, and progress in cancer research are likely bolstering investor confidence in its future growth opportunities.

17.03.2026 - NTRA Stock was up 5.1%

• Natera (NTRA) reported impressive fourth-quarter results, exceeding earnings and revenue estimates, which likely boosted investor confidence in the company's performance.
• Positive interim futility analysis from Allogene Therapeutics' ALPHA3 trial, utilizing Natera's CLARITY™ MRD assay, showcased the effectiveness of Natera's technology in identifying high-risk patients and potentially preventing relapse in large B-cell lymphoma cases.
• Despite holding a Zacks Rank #4 (Sell) due to estimate revisions, the initiation of coverage by William Blair with an "outperform" recommendation highlighted Natera's strong position in the growing MRD testing market, projecting significant revenue growth potential.
• The mixed share price performance evaluation, indicating undervaluation by DCF model but overvaluation by P/S ratio, suggests varying perspectives on Natera's future valuation and growth prospects, leaving investors with contrasting views on the stock's true value.

23.03.2026 - NTRA Stock was down 5.2%

• The recent bearish movement in Natera's stock could be attributed to:
• Profit-taking by insiders: Co-founder Sheena Jonathan and family trusts selling a significant number of shares could have indicated a lack of confidence in the short-term performance of the stock.
• Overvaluation concerns: Despite the recent price surge, valuation metrics like the Price-to-Sales (P/S) ratio suggesting overvaluation might have led investors to capitalize on their gains.
• Market dynamics: While Natera's stock experienced a downward trend, other companies in the healthcare sector, such as UFP Technologies, Mettler-Toledo, and Viatris, saw substantial gains, potentially diverting investor attention away from Natera.
• Overall market sentiment: The reopening of the Strait of Hormuz resulting in decreased logistics and energy costs may have redirected investor focus to companies directly benefiting from these changes, impacting Natera's stock negatively.

16.03.2026 - NTRA Stock was down 6.8%

• The bearish movement in Natera's stock today could be attributed to the mixed evaluations of its share price performance, with conflicting assessments of undervaluation and overvaluation.
• Despite being positioned to capture a significant share of the $20 billion MRD opportunity and receiving an 'Outperform' rating from William Blair, concerns about overvaluation and insider selling may have dampened investor sentiment.
• The positive interim results from Allogene Therapeutics’ ALPHA3 trial, showcasing the effectiveness of cema-cel in reducing MRD levels in lymphoma patients, could have been overshadowed by broader market uncertainties or profit-taking activities.
• Natera's strong growth potential and competitive advantages in the diagnostics sector may still underpin its long-term prospects, despite short-term market fluctuations.

06.04.2026 - NTRA Stock was up 5.1%

• The bullish movement in Natera's stock today is linked to positive developments such as an "Outperform" rating from William Blair, a patent victory, and promising study results for its Signatera assay.
• The selling of shares by key executives like Sheena Jonathan, John Fesko, and CEO Steven Chapman to cover tax obligations initially raised concerns. However, these pre-arranged transactions, in light of positive news, likely reassured investors about the company's health and future prospects.
• Strategic selling of shares by company insiders under Rule 10b5-1 plans, despite the stock being down year-to-date, may indicate a prudent approach to finance management while maintaining confidence in company performance.
• The combination of positive company developments and strategic insider selling likely fueled the bullish movement in Natera's stock today, demonstrating a blend of financial responsibility and investor confidence in the company's growth trajectory.

30.03.2026 - NTRA Stock was up 5.1%

• The company revealed its first-quarter financial results and held a conference call, potentially boosting investor confidence and fueling the bullish movement.
• Insider selling by the co-founder and CEO, aimed at covering tax obligations, initially raised concerns but a clarified context of these sales being part of a pre-arranged trading plan may have alleviated any negative impact.
• Despite Natera's current lack of profitability, positive court rulings and new analyst coverage could have positively influenced investor sentiment, contributing to the bullish market performance.
• Taken together, positive updates on financial results, structured insider trading activities, and external factors like court decisions and analyst coverage likely played a role in Natera's recent strong bullish trend.

29.03.2026 - NTRA Stock was down 5.0%

• The downward trend in Natera's stock price could be linked to notable insider selling activity by directors such as Roelof Botha, Eric H. Rubin, and Ruth Williams Brinkley. This activity may have sparked concerns among investors regarding the company's future outlook.
• Despite the release of positive information regarding Natera's recent clinical evidence for its Prospera transplant test, which could potentially boost revenue, the overall market sentiment may have been clouded by the insider selling, as well as the company's negative net margins and ROE.
• While the initial increase in M&T Bank Corp's stake could have been viewed as a positive development, investor focus appeared to shift towards the insider selling and the company's financial difficulties, contributing to today's bearish movement in the stock.

10.03.2026 - NTRA Stock was down 5.6%

• The bearish movement in Natera's stock today could be attributed to profit-taking by investors after a recent uptrend following positive legal outcomes.
• The appointment of Director Eric H. Rubin to the insider roster may have raised concerns among investors about potential future decisions or changes within the company.
• Despite the positive rulings in the patent disputes and the increase in royalties, the market may have reacted negatively due to uncertainties surrounding the financial impact on Natera and its competitors.
• The insider activity of the Executive Chairman, Matthew Rabinowitz, exercising stock options and selling shares to cover tax obligations could have also contributed to the downward pressure on the stock price as investors may interpret this as a lack of confidence in the company's future prospects.

10.03.2026 - NTRA Stock was down 7.8%

• The court ruling awarding Natera a 30% royalty on post-injunction revenues from MRD patents against ArcherDx and Invitae was initially seen as a positive development, leading to a slight increase in premarket trading. However, the market may have reacted negatively due to concerns about high cash burn and challenges in clinical trials and reimbursement.
• The addition of director Eric H. Rubin to Natera's insider roster, while providing transparency, did not have a significant impact on the stock movement.
• Despite the favorable court decisions strengthening Natera's intellectual property portfolio, the market may have been influenced by the potential financial implications of the royalty payments on the company's overall performance.
• Analysts revising earnings upwards and the positive influence on stock valuation could indicate long-term growth potential, but the current overvaluation concerns raised in the analysis may have contributed to the bearish market movement.

08.04.2026 - NTRA Stock was down 6.0%

• Natera's strong revenue growth and milestone of processing over 1 million tests in a quarter showcased its continued expansion and market demand for its services.
• The wider loss per share than expected could have contributed to the bearish movement in the stock, despite positive revenue performance.
• The sale of shares by the Executive Chairman to cover tax obligations may have also impacted investor sentiment, leading to a decline in the stock price.
• Overall, while Natera's operational performance remains robust, market reaction to the earnings miss and insider selling likely drove the bearish movement in the stock today.